May 20, 2014 – Dr. L'Heureux to be the keynote speaker at the French National Meeting on Biomaterials Research ("Assises Nationales de la Recherche en Biomatériaux"; Autrans, France).
May 5, 2014 - Dr. McAllister to present Cytograft’s unique and successful business model at the Regenerative Medicine conference in San Francisco.  Program details can be found here.
April 27, 2014 – Dr. L'Heureux to present recent results regarding the use of "Cell-synthesized extracellular matrix particles for tissue engineering and aesthetic applications" at the Experimental Biology 2014 meeting in San Diego. Link to the published abstract in the FASEB Journal here.
April 25, 2014 - Dr. McAllister to present on the convergence of tissue engineering and bioprinting at the ISCT annual meeting. Meeting agenda is here.
March 16, 2014 – Dr. McAllister publishes a perspective manuscript in MedNous. Full text is available here.
March 14, 2014 – A patent application describing the new abdominal aorta aneurism (AAA) repair device created by Cytograft is published by the USPTO (Patent application 20140081385)
March 14, 2014 – Dr. L'Heureux to speak at the INSERM Workshop #226 "3D cell culture bridges the gap between cell culture and live tissue" (Bordeaux, France).
March 14, 2014 - Dr. McAllister presents data in an invited lecture at the Ohio State University wound Care Conference. Conference program can be found here.
October 28, 2013 – Dr. L’Heureux to hold a seminar at the Vascular Surgery Institute of Fudan University Medical School  (Shanghai, China). 
October 7, 2013 - Results from the "First human use of an allogeneic tissue-engineered vascular graft for hemodialysis access" are published in the Journal of Vascular Surgery (available as Epub ahead of print). Link to publisher here.
December 5, 2013 - Drs. L’Heureux and McAllister publish in the 2012 World Stem Cell Report.  In this invited manuscript, Cytograft’s founders propose revised regulatory standards for autologous cell therapies.  See the full length manuscript in Regenerative Medicine here.
 

Legal Notice

THE FOLLOWING TERMS OF USE GOVERN THE USE OF THE CYTOGRAFT.COM WEB SITE. PLEASE READ THEM CAREFULLY. IF YOU DO NOT AGREE WITH THESE TERMS OF USE, YOU ARE NOT GRANTED PERMISSION BY CYTOGRAFT TISSUE ENGINEERING, INC. TO ACCESS OR OTHERWISE USE THIS SITE. BY USING THIS SITE, YOU SIGNIFY YOUR AGREEMENT TO ALL TERMS, CONDITIONS AND NOTICES CONTAINED OR REFERENCED HEREIN.

Intellectual Property Rights
All materials contained in the Site are protected by law, including, but not limited to, United States copyright and trademark law, as well as other state, national, and international laws and regulations. The contents of the Site are Copyright © 2009 Cytograft Tissue Engineering, Inc. or its licensors or suppliers, all rights reserved. Cytograft also owns a copyright in the Site as a collective work or compilation or both, and in the selection, coordination, arrangement, and enhancement of its content. Republication or citation of any content generated by or from the Site without Cytograft' s written consent is prohibited. You agree not to copy, modify, adapt, frame, mirror, reproduce, translate, distribute, transmit, reverse engineer, decompile, or disassemble any aspect of the Site, except as expressly allowed by these Terms of Use. All product names, whether or not appearing in large print, italics or with the trademark symbol, are trademarks of Cytograft, its affiliates, related companies or its licensors or joint venture partners. Any use of such marks without the express written permission of Cytograft is strictly prohibited. Unauthorized use of any material contained on this Site may violate, among others, copyright laws, trademark laws, trade secret laws, the laws of privacy and publicity, and communications statutes and regulations. Cytograft actively and aggressively enforces its intellectual property rights to the fullest extent of the law.